Physician profile

Erwin Mermelstein

Cardiovascular Disease · East Brunswick, NJ

NPI 1538102843

$1,328.55

in general payments reported to CMS, 2019-2025

19 companies · $53.72 in 2025

The $53.72 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$329.64

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $521.09 2021-2024
Boston Scientific Corporation $248.36 2019-2023 Watchman Access System, Watchman
E.R. Squibb & Sons, L.L.C. $124.46 2022-2024 Camzyos
Amgen INC. $72.81 2019-2024 Repatha
Janssen Pharmaceuticals, INC $54.27 2020-2021
Gilead Sciences, INC. $53.20 2019
Merck Sharp & Dohme LLC $35.94 2021-2022
Abiomed $28.61 2023 Impella
Atricure, INC. $24.61 2024
Abbott Laboratories $22.62 2024 Amplatzer Amulet
Heartflow, INC. $19.92 2025
Pfizer INC. $18.80 2025
Kiniksa Pharmaceuticals International, Plc $16.57 2024 Arcalyst
Tactile Systems Technology INC $16.11 2020
Esperion Therapeutics, INC. $15.05 2022
Show all 19 companies
CompanyGeneral paymentsYearsTop products
Bayer Healthcare Pharmaceuticals INC. $15.00 2025
Sanofi-Aventis U.S. LLC $14.95 2022
Amarin Pharma, INC. $13.34 2020
Kiniksa Pharmaceuticals, LTD. $12.84 2023 Arcalyst

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Erwin Mermelstein

$1,328.55

in general payments reported 2019-2025

Years
2019-2025
Top company
Novartis Pharmaceuticals Corporation
Context
The $53.72 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/251343/erwin-mermelstein

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.